CalciMedica (NASDAQ:CALC – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.14, Zacks reports.
CalciMedica Stock Up 4.0 %
CalciMedica stock opened at $2.07 on Friday. The business has a 50-day simple moving average of $2.41 and a 200 day simple moving average of $3.19. The stock has a market cap of $27.91 million, a price-to-earnings ratio of -1.92 and a beta of 1.20. CalciMedica has a 52 week low of $1.83 and a 52 week high of $6.27.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of CalciMedica in a report on Tuesday, March 4th.
CalciMedica Company Profile
CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
See Also
- Five stocks we like better than CalciMedica
- Technology Stocks Explained: Here’s What to Know About Tech
- Microsoft’s Big Malaysia Bet Could Pay Off for Investors
- Using the MarketBeat Dividend Tax Calculator
- The 5 Most Oversold Stocks on the Market Are…
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Archer Aviation Stock Sees Surge in Institutional Buys
Receive News & Ratings for CalciMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CalciMedica and related companies with MarketBeat.com's FREE daily email newsletter.
